RE: Porky11 Jul 2022 22:29
Porky9 Premium Member
Posted in: VAL
Posts: 5,198
Price: 52.25
Strong Buy
Valuation Re-Rate02 Nov 2021 00:40
What we are seeing is a rerate of the company
We have been materially undervalued for so long that many have just got used to it but it’s as clear as day to see when you compare us to our peers.
My stance remains at 74p to 85p pre licensing as continually stated. 80p being £52m mcap bang on the peer group average and significantly higher after deals.
Let’s explore this further based on deals.
Currently we can’t know what Valirx are negotiating behind the scenes or their success in negotiations. We can only speculate. What we do know is that taking curved balls out of the equation, both 201 and 301 are packaged ready to go and so is possibly 401 as its a reformulated generic drug with a much shorter route to market. So potentially three horses in the stable ready to run.
From my own independent research and please do your own, the Prostate cancer drugs market last year, where 201 is positioned, was worth $11.2bn USD and growing
Meanwhile, the Endometriosis drugs market where 301 is positioned, is worth just short of a $2bn USD market size with expected growth to $2.2bn by 2027
The pancreatic cancer drugs market last year, where 401 is positioned, was worth $2.6bn last year and expected to rise to almost $3.8 by 2027 So we are talking big numbers here.
Our mcap tonight at 53p is still a mere £ 34m, I want to post that again because some are just not getting it, we are valued at £ 34m – This is not just materially undervalued, it is plain farcical.
Now we have explored from our peer group Sareum at £ 223m mcap and I believe we are potentially stronger and can overtake this Biotech. Mentioned a couple of days back was also RedX Pharma from our peer group, which spookily is also valued at £ 223m mcap.
RedX secured a back loaded $200m licensing deal on milestones including tiered royalties in mid-single digit percentages, based on any future net sales. The upfront was $10m payment. On the day of the announcement the deal boosted their mcap value, marked up immediately by £ 30m and over the following 7 days the SP rallied by a further £ 100m value.
Now I’m not saying Valirx will do the same, all deals are different and have their merits but come on.
We have potentially THREE deals here to be done not just one. I could be totally wrong in my calculation but If I were a betting man, I would say 201 alone could be worth £200m and £10m down like the RedX deal. As such our market cap should run towards same, if it did, we would be looking at a circa £ 160m mcap value or £ 2.46 share price NOT a 54p one with the other deals still to come.
Uncannily, that’s slightly over OB’s target.
The market currently wants to see proof of deals. I believe we will see that shortly and when we do, we will see that step change in the share price and further rally, in the meantime the MMs are getting prepared for